Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2004-004620-12-GB
EUCTR2004-004620-12-GB
Active, not recruiting
Phase 1

Assessment of normal release morphine in the management of dyspnoea

Royal Marsden Hospital0 sites30 target enrollmentFebruary 17, 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBreathlessness of any cause in cancer patients are identified and treated with normal release morphine which has been shown to be both effective and safe.The idea of the trial is to see if there will be an added benefit to gentle dose increments. There are no placebos used.

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Breathlessness of any cause in cancer patients are identified and treated with normal release morphine which has been shown to be both effective and safe.The idea of the trial is to see if there will be an added benefit to gentle dose increments. There are no placebos used.
Sponsor
Royal Marsden Hospital
Enrollment
30
Status
Active, not recruiting
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 17, 2005
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Royal Marsden Hospital

Eligibility Criteria

Inclusion Criteria

  • •?A score of equal or more than 3 on the Modified Borg scale at rest
  • •?Cancer diagnosis
  • •?Inpatient at The Royal Marsden Hospital
  • •?Aged over 18 years
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •?A score for breathlessness of less than 3 on the Modified Borg scale at rest
  • •?Non cancer diagnosis
  • •?Cognitive impairment
  • •?Planned therapeutic procedure / anticancer treatment for breathlessness during the trial time.
  • •?Patients taking opioids for moderate to severe pain e.g morphine, fentanyl, oxycodone.
  • •?Aged under 18 years

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 3
Effect of morphin in prognose of Anterior MIAcute Anterior ST Elevatiom Myocardial Infarction.ST elevation (STEMI) myocardial infarction of anterior wallI21.0
IRCT20230102057018N1Research Assistant of Tabriz University of Medical Sciences200
Not yet recruiting
Not Applicable
Identification of effective morphine administration route for postoperative pain in robot-assisted rectal resection (prospective intervention, open label test)rectal cancer
JPRN-UMIN000035096Sapporo Medical University School of Medicine Clinical Department48
Not yet recruiting
Phase 2
Efficacy of sustained release morphine and immediate release morphine for treatment of cancer pain a comparative studyHealth Condition 1: C00-D49- Neoplasms
CTRI/2022/01/039252Gaurav Sharma
Recruiting
Phase 2
The effect of morphine with nebulizer mask in the treatment of acute respiratory distress in adult patients with Covid-19
IRCT20211112053042N2Karaj University of Medical Sciences60
Completed
Not Applicable
ong-term effects of routine morphine infusion in newborns who received ventilatory supportgevoeligheid warmte/ koude, functioneren HPA-asdetection thresholdsstress response10028920
NL-OMON29866Erasmus MC, Universitair Medisch Centrum Rotterdam192